SINGAPORE AIRLINES LTD (SGX:C6L)
UNITED OVERSEAS BANK LTD (SGX:U11)
DBS GROUP HOLDINGS LTD (SGX:D05)
KEPPEL CORPORATION LIMITED (SGX:BN4)
SINGTEL (SGX:Z74)
THAI BEVERAGE PUBLIC CO LTD (SGX:Y92)
CAPITALAND LIMITED (SGX:C31)
ASCENDAS REAL ESTATE INV TRUST (SGX:A17U)
FRASERS CENTREPOINT TRUST (SGX:J69U)
FRASERS LOGISTICS & COMMERCIAL TRUST (SGX:BUOU)
SBS TRANSIT LTD (SGX:S61)
BOUSTEAD SINGAPORE LIMITED (SGX:F9D)
JAPFA LTD. (SGX:UD2)
CSE GLOBAL LTD (SGX:544)
KOUFU GROUP LIMITED (SGX:VL6)
UG HEALTHCARE CORPORATIONLTD (SGX:8K7)
Singapore Stock Picks - Go With The Flow, Don’t Fight The Market
- Our latest Singapore stocks top picks:
- Singapore Airlines (SGX:C6L),
- UOB (SGX:U11),
- DBS (SGX:D05),
- Keppel Corp (SGX:BN4),
- SingTel (SGX:Z74),
- Thai Beverage (SGX:Y92),
- CapitaLand (SGX:C31),
- Ascendas REIT (SGX:A17U),
- Frasers Centrepoint Trust (SGX:J69U),
- Frasers Logistics & Commercial Trust (SGX:BUOU),
- SBS Transit (SGX:S61),
- Boustead Singapore (SGX:F9D),
- Japfa (SGX:UD2),
- CSE Global (SGX:544),
- Koufu (SGX:VL6),
- UG Healthcare (SGX:8K7).
Change in favourites; Go with the flow
- Continue from: Singapore Stock Strategy - CGS-CIMB Research 2020-11-17: First Earnings Upgrade Offers Hope; Mean Reversion Ahead.
- We were previously prepared to rotate into cyclicals and beaten down sectors if a COVID-19 vaccine was widely available. However the musical chair of switching into these names were violent after the Pfizer vaccine news broke last week. Yield instrument (REITS) were generally used as a funding source into Capital Goods, Transport and Gaming.
- We do not see a point in going against the market. The caveat is one has to look beyond two years for earnings normalisation as the real struggle against the COVID-19 virus is far from over. Critical mass deployment of any vaccine will take time and, in our view, clarity is only likely by mid-2021 globally, but the natural tendency among investors to look ahead will trigger the sustained shift into 2020-beaten down sectors.
- Arguably, 2021 could be a better year than this one as our economist forecasts a GDP growth of 5.3% (2020: -5.7%), seeking reassurance from the recent discovery of COVID-19 vaccines that the trend of economic normalisation would start materialising next year.
Defensive earnings recovery: Upgrade Banks from Neutral to Overweight.
- We believe Singapore banks’ earnings recovery is sustainable in FY21F as credit costs likely peaked in 2020 with asset quality holding steady going forward. As book value risks dissipate, we expect improving ROE towards double-digits by FY23F to drive valuations back to historical mean of 1.3x.
- The banks’ aggressive efforts to grow non-interest income to buffer their subdued interest income could still see room to surprise on the upside.
- Resumption of dividends to pre-COVID-19 levels is also a key catalyst.
- See Singapore Banks - CGS-CIMB Research 2020-11-06: Focusing Less On BV Risks, More On ROE.
Vaccine beneficiaries: Upgrade Transport from Neutral to Overweight.
- The transport sector has underperformed the index by c. 30% year-to-date, even with the recent outperformance, suggesting ample headroom for upside on any positive development, including more bilateral travel arrangements, as well as reciprocal leisure travelling, especially from China.
- Domestically, Singapore is well prepared to enter into phase 3 with broader economy activities by the end of 2020 or early-2021 which could see positive demand for land transport (ComfortDelGro (SGX:C52)).
- See also recent SGX market update: SGX Transportation Stocks On The Move With 11% Gains In Early November.
Singapore Stock Picks
- Our stock picks are based on
- recovery theme,
- value, and
- yield with growth prospects.
- Large cap stocks that are perceived as a recovery proxy are
- Singapore Airlines (SGX:C6L) and Thai Beverage (SGX:Y92) (borders reopening),
- UOB (SGX:U11) and DBS (SGX:D05) (earnings recovery and ROE expansion),
- CapitaLand (SGX:C31) (improving operating metrics across segments - residential sales, retail and lodging).
- Keppel Corp (SGX:BN4) belongs to the value category with finalisation of O&M strategic review by 1Q21F a near-term catalyst.
- We still like SREITs as the sector trades at c.5% 12-month forward dividend yield, midway between the average and +1 s.d. long term yield band, and at 1.06x P/BV. Whilst our sub-sector ranking is retail, industrial, office and hospitality, pegged by order of most-liked to least-liked preference, we continue to be selective on stock selection. Our REITs picks are
- Frasers Centrepoint Trust (SGX:J69U) as a pure suburban mall landlord in Singapore and as we expect it to see a faster recovery compared to peers. The stock is trading at 0.9x P/BV versus its pre-COVID-19 peak of 1.3x P/BV.
- Frasers Logistics & Commercial Trust (SGX:BUOU) which offers strong inorganic growth potential through its deep sponsor pipeline and attractive valuations at c.6.1% FY21F dividend yield.
- Ascendas REIT (SGX:A17U) (+2.4% year-to-date) is another pick, being a laggard vs. its industrial peers such as Mapletree Industrial Trust (SGX:ME8U) and Mapletree Logistics Trust (SGX:M44U) that have outperformed by c.13-15%.
- We replace NetLink Trust (SGX:CJLU) with SingTel (SGX:Z74) as a non-REIT yield play. Catalysts are
- potential award of a full digital bank licence together with Grab,
- 100% FY3/21F dividend payout vs. our expectations of 75% and
- H-o-h earnings recovery in 2HFY3/21F.
- Small caps: SBS Transit (SGX:S61) and Koufu (SGX:VL6) are our picks on the recovery of the domestic economy into Phase 3 as social distancing measures ease further.
- We like Boustead Singapore (SGX:F9D)’s strong earnings momentum, which is likely to sustain into 2H21F, driven by stronger energy segment contribution and recovery from the property segment. The stock is trading at 4x ex-cash FY22F P/E.
- We continue to like CSE Global (SGX:544) for the steady dividend yield of c.6%, Japfa (SGX:UD2) for its undemanding valuations of 6x FY21F P/E, -0.5 s.d. below mean as the market is still giving full credit of sustained dairy and poultry margin.
- We keep UG Healthcare (SGX:8K7) due to its undemanding valuations (9x FY23F), assuming more normalised profits that are backed by +59% y-o-y manufacturing capacity expansion to 4.6bn pcs/ p.a.
- See PDF report attached below for complete analysis.
Recent reports on our Singapore stock picks:
- Singapore Airlines - CGS-CIMB Research 2020-11-16: Upgrading SIA To ADD On Improving Risk-Reward.
- DBS - CGS-CIMB Research 2020-11-07: Provisions Taken Up Front; Upgrade To ADD.
- UOB - CGS-CIMB Research 2020-11-04: The Worst Could Be Over; Upgrade To ADD.
- Keppel Corporation - CGS-CIMB Research 2020-10-29: Looking Forward To 100-Day Plan Outcome.
- SingTel - CGS-CIMB Research 2020-11-12: 1HFY21 Some Positives Amid Weak Results.
- CapitaLand - CGS-CIMB Research 2020-11-04: Signs Of Recovery.
- Ascendas REIT - CGS-CIMB Research 2020-11-10: Acquisitions Galore.
- Frasers Centrepoint Trust - CGS-CIMB Research 2020-11-03: Warding Off COVID-19 Impact.
- Frasers Logistics & Commercial Trust - CGS-CIMB Research 2020-11-06: Stable Performance.
- SBS Transit 3Q20 Update - CGS-CIMB Research 2020-11-12: Wheels In Motion.
- Boustead Singapore - CGS-CIMB Research 2020-11-17: Firing On All Cylinders.
- Japfa - CGS-CIMB Research 2020-10-30: Indonesia Poultry & Dairy Beats Expectations.
- CSE Global - CGS-CIMB Research 2020-11-09: 3Q20 Systems Intact.
- UG Healthcare - CGS-CIMB Research 2020-11-06: A Strong Start To The Year.
LIM Siew Khee
CGS-CIMB Research
|
Singapore Research Team
CGS-CIMB Research
|
https://www.cgs-cimb.com
2020-11-17
SGX Stock
Analyst Report
4.570
SAME
4.570
22.520
SAME
22.520
25.510
SAME
25.510
6.460
SAME
6.460
3.100
SAME
3.100
0.700
SAME
0.700
3.420
SAME
3.420
3.200
SAME
3.200
2.890
SAME
2.890
1.500
SAME
1.500
3.600
SAME
3.600
1.200
SAME
1.200
1.000
SAME
1.000
0.600
SAME
0.600
0.860
SAME
0.860
1.700
SAME
1.700